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An established culture of Aspergillus fumigatus MBC-F1-10 proved to be very receptive to external stimuli
and reacted with the production of secondary metabolites which were undetectable when the fungus was
grown under standard conditions. Firstly, co-cultivation with the type strain of Streptomyces bullii, an
isolate from hyper-arid Atacama desert soil, led to the isolation of ergosterol 1, seven metabolites
belonging to the diketopiperazine alkaloids; brevianamide F 2, spirotryprostatin A 3, 6-methoxy
spirotryprostatin B 4, fumitremorgin C and its 12,13-dihydroxy derivative (5–6), fumitremorgin B 7, and
verruculogen 8, in addition to 11-O-methylpseurotin A 9 and its new isomer 11-O-methylpseurotin A2 10.
In an independent experiment, addition of N-butyryl-DL-homoserine lactone to the culture medium led to
the production of emestrins A and B (11–12). Neither microbe produced these compounds when cultured
alone. The structures of all compounds were elucidated using NMR spectroscopic techniques and mass
spectrometric analysis. The isolated compounds were tested for their potential antibacterial and
antiprotozoal activities.
Introduction
Microbial secondary metabolites have been considered one of
the best resources for drug discovery.1 Up to early 2013, more
than 42 000 natural compounds have been characterized from
microorganisms and higher fungi.2 Parallel to this increase in
the rate of isolation of new microbial natural products, the
rate of re-isolation of known secondary metabolites has also
increased significantly in the past few years.3 Given the fact
that microorganisms naturally interact with each other,
simulating microbial competition for nutrition and space is
regarded as a major route for the induction of bioactive
secondary metabolites.4 Thus, mimicking the natural micro-
bial environment, cultivation of two different microbial strains
together in one culture vessel (i.e., competing co-culture)
allows direct interaction between these microbes which may
lead to the induction of new secondary metabolites not
previously observed in independent culture of the strains.
This phenomenon might be due to microbial crosstalk or
chemical defence mechanisms leading to the switching on of
cryptic biosynthetic genes in a second microorganism as the
result of a signal from the other microorganism.5,6
Most previous co-culture experimental studies reported an
increase in biological activity without the identification of the
secondary metabolites responsible for this effect, confirmed
the induction of antibiotic biosynthesis but not the induction
of specific metabolic pathways or increased yields of pre-
viously described metabolites.7,8 However, the induction of a
previously unexpressed biosynthetic pathway leading to the
production of new secondary metabolites in response to co-
culture is less often described in the literature. Fenical and co-
workers reported that the competing co-culture of the marine-
derived fungus Pestalotia sp. with a marine a-proteobacterium
(strain CNJ-328) led to the production of the new antibiotic,
pestalone9 and subsequently, culturing the same bacterium
with the marine-derived fungus Libertella sp. resulted in the
discovery of four potent cytotoxic pimarane diterpenoids,
libertellenones A–D.4 They also isolated two new antibacterial
cyclic depsipeptides, emericellamides A–B through the co-
culture of the marine-derived fungus Emericella sp. and the
obligate marine actinomycete Salinispora arenicola.10 More
recently, a new antibiotic-antitumor metabolite, glionitrin A
was isolated during the co-culture of a mine drainage-derived
Aspergillus fumigatus and a mine drainage-derived
Sphingomonas isolate strain KMK-001,11 while co-culturing A.
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fumigatus with Streptomyces peucetius led to the production of
the new formyl xanthocillin analogue fumiformamide.12
Interaction of the two fungi Penicillium pinophilum and
Trichoderma harzianum led to the discovery of a new prenylated
polyketide, secopenicillide C,13 while co-cultivation of
Pseudomonas aeruginosa and Candida albicans resulted in
induction of a bacterial gene cluster required for phenazine
biosynthesis.14 This listing does not aim at complete coverage,
and the reader is referred to excellent recent review articles
covering bacterial-fungal interactions15 as well as the control
of secondary metabolite biosynthetic pathways in the genus
Aspergillus.16
In this communication, we report on another example of
the induction of a presumed fungal biosynthetic pathway in
response to microbial co-culture. The addition of the type
strain Streptomyces bullii,17 an isolate from hyper-arid Atacama
Desert soil, to an established culture of A. fumigatus MBC-F1-
10 has led to the isolation of ergosterol (1), seven metabolites
belonging to the diketopiperazine (DKP) class of alkaloids;
brevianamide F (2), spirotryprostatin A (3), 6-methoxy spiro-
tryprostatin B (4), fumitremorgin C and its 12,13-dihydroxy
derivative (5–6), fumitremorgin B (7), and verruculogen (8), in
addition to two metabolites from the rare class of pseurotins,
11-O-methylpseurotin A (9) and its new isomer 11-
O-methylpseurotin A2 (10). None of these compounds were
observed in pure independent cultures of the fungus or the
bacterium and all of them are considered to be of fungal origin
due to their chemical nature.
Moreover, the addition of the known quorum sensing
metabolite, N-butyryl-DL-homoserine lactone (HSL), to the
culture media of the fungus led to the isolation of emestrins
A–B (11–12) which were not traced in the pure fungal culture.
The isolated compounds were tested for their potential
antibacterial and antiprotozoal activities. Diseases caused by
parasitic protozoa affect many people around the world,
notably, Chagas’ disease (American trypanosomiasis), sleeping
sickness (human African trypanosomiasis), and leishmaniasis.
The treatment for these diseases mainly depends on
chemotherapy.18 Although several antiparasitic drugs are
available, most have toxic side effects, and furthermore
development of drug resistance is commonly observed.
Therefore, searching for new and effective drugs against
neglected tropical diseases (NTD) is needed. Since DKPs with
diverse skeletons were reported to have efficient trypanocidal
activity, especially disulfide-containing DKPs like gliotoxin
which showed nanomolar activity against the whole cell
parasite,19 DKPs isolated from Aspergillus fumigatus MBC-F1-
10 were tested for their potential antiparasitic activity against
Trypanosoma brucei brucei and Leishmania donovani. They were
also tested against normal human MRC5 cells (diploid foetal
lung fibroblasts) as a counter-screen for indications of toxicity
and non-selective inhibition.
Results and discussion
Streptomyces sp. strain C2, which was recently proposed as the
type strain of Streptomyces bullii,17 was one of several putatively
novel Streptomyces strains from the Atacama Desert included
in our chemical screening programme.20 Strain C2 was
initially fermented in yeast-extract-malt extract broth21 on a
rotary incubator for eight days at 28 uC. After extraction and
fractionation, a significant amount of ergosterol22 (1), a strictly
fungal metabolite, was isolated as pure crystals from the
hexane fraction. Moreover, HPLC purification of the dichlor-
omethane fraction resulted in the isolation of several DKPs
which had previously been described from various fungal
strains (vide infra). These results prompted us to re-cultivate
the bacterial sterile ferment on ISP2 agar plates with
incubation at 30 uC, which led to the isolation of a pure
culture of strain C2 in addition to an unknown fungal strain,
labelled MBC-F1-10. The fungus was purified by subculture on
malt extract agar plates, and identified as Aspergillus fumigatus
based on the comparison of the sequence of its ITS region with
previously published sequences obtained from GenBank.
From a chemotaxonomic point of view, the identification of
the fungus was also reassuring, since strains of A. fumigatus
have repeatedly been shown to be capable of producing
secondary metabolites of both the DKP class of natural
products including representatives of the fumitremorgin and
the verruculogen families, and pseurotin congeners.23
Quite unexpectedly, chemical analysis of the fungus A.
fumigatus MBC-F1-10 cultivated on malt extract medium
(Fig. 1a) resulted in a sparse metabolite profile, with hardly
any dominating peaks visible in the LC-MS chromatogram. As
Fig. 1 HPLC profiles of different bacterial/fungal co-culture approaches. (a)
bacteria alone; (b) fungus alone; (c) fungal-bacterial co-cultivation; (d) fungus
with bacteria-free ISP2 medium; (e) fungus with bacterial MeOH extract; (f)
fungus with dead bacterial cells; (g) fungus with HSL.





















































































a control, the S. bullii strain was also cultivated alone on ISP2
medium (Fig. 1b), resulting in a similar finding. However,
deliberately co-cultivating both microorganisms together, i.e.
addition of a fresh culture of S. bullii strain C2 to an
established three day old culture of A. fumigatus MBC-F1-10,
resulted in a very complex LC-MS profile, which was confirmed
in two subsequent analogous experiments (Fig. 1c, only one
representative HPLC chart depicted). Seven metabolites
belonging to the DKP alkaloid family were isolated, specifically
brevianamide F24 (2), spirotryprostatin A25 (3), 6-methoxyspir-
otryprostatin B26 (4), fumitremorgin C27 (5) and its 12,13-
dihydroxy derivative28 (6), fumitremorgin B29 (7), and verru-
culogen30 (8), in addition to two metabolites from the rare
class of pseurotins, 11-O-methylpseurotin A31 (9) and its new
isomer 11-O-methylpseurotin A2 (10). All of these compounds
were consistently detected in all three experiments, and based
on their structures and their known fungal origin it is
reasonable to assume that they were produced by the fungus
and not by the bacterium during the fungal bacterial co-
culture.
In order to gain insight into the possible mechanism of
induction of the biosynthesis of these fungal metabolites by
the streptomycete, an additional series of experiments was
performed. To an established fungal culture cultured by itself
and obtained as described above, was added a treated culture
of the streptomycete cultured on its own, as follows: A
bacteria-free medium only consisting of ISP2 medium (to rule
out induction of media components) (Fig. 1d); an extract of the
bacterial biomass obtained with MeOH (Fig. 1e), and a full
bacterial culture broth, but inactivated by autoclaving (Fig. 1f).
In all three cases, induction of the fungal metabolites 2–10 was
not observed. However, addition of N-butyryl-DL-homoserine
lactone, a known bacterial quorum sensing compound
(Fig. 1g), to the established fungal culture led to induction
of the known cyclic DKPs emestrin A32 (11) and B33 (12). It is
worth noting that neither 11 nor 12 could be detected in the
co-cultivation experiment represented in Fig. 1c, while none of
the fungal metabolites 2–10 were observed in this experiment.
Compounds 1–9, 11, and 12 were identified based on their
accurate mass analysis and comparison of their MS and NMR
spectral data with those reported in the literature. The
HRESIMS data of 10 established its molecular formula as
C23H27NO8, the same as that of 11-O-methylpseurotin A (9).
Both compounds displayed virtually identical UV and IR
spectra. The analysis of the 1H and 13C NMR data of 10
(Table 1) indicated the presence of a monosubstituted benzene
ring, a disubstituted cis double bond (J = 10.9 Hz), one
aliphatic and one allylic methyl group, two O-methyl groups,
and three carbonyls including one a,b-unsaturated ketone and
one amide. The 1H- and 13C NMR data of both compounds
were reminiscent of each other with the exception of slight
variations in chemical shifts at four positions (Table 1, ESI3).
The analysis of COSY and HMBC spectra (Table 1, Fig. 2)
revealed that the planar structure of compound 10 was
identical to that of 9, thus indicating that they were
stereoisomers. Analysis of the 1D NMR data (Table S1, ESI3)
suggested that both compounds should differ with regard to
the relative configuration of the pyrrolidinone ring, and a
comparison of the 13C NMR data of this substructure with that
reported for the structurally related compounds, pseurotin A34
Table 1 NMR spectroscopic data (600 MHz at 298 K) for 11-O-methylpseurotin A2 (10)
Position dH, mult. (J in Hz)
a dC, mult
a dH, mult
b (J in Hz) dC, mult
b HMBCc
2 184.4, C 186.8, C
3 113.3, C 111.4, C
4 198.1, C 199.8, C
5 88.5, C 88.2, C
6 167.9, C 167.5, C
8 95.4, C 97.0, C
9 4.78, s 76.5, CH 4.62 (d, 6.2) 75.6, CH 4, 6, 8
10 4.56 (d, 6.4) 70.3, CH 4.48 (t, 5.4) 70.4, CH 2, 11, 12
11 4.28 (dd, 6.5, 9.1) 77.6, CH 4.17 (dd, 5.5, 9.3) 77.1, CH 2, 10, 13
12 5.27 (t, 10.7) 124.7, CH 5.31 (t, 10.9) 125.6, CH 14
13 5.82, m 140.3, CH 5.62, m 136.9, CH 11
14 2.10, m 21.4, CH2 2.04, m 20.7, CH2 12, 13, 15
1.97, m
15 0.98 (t, 7.5) 14.3, CH3 0.87 (t, 7.6) 14.1, CH3 13, 14
16 1.77, s 5.8, CH3 1.64, s 5.6, CH3 2, 3, 4
17 193.3, C 194.7, C
18 134.0, C 134.8, C
19/23 8.21 (d, 7.9) 129.9, CH 8.11 (d, 7.7) 129.6, CH 17, 21
20/22 7.47 (t, 7.8) 128.7, CH 7.52 (t, 7.8) 128.3, CH 18
21 7.60 (t, 7.2) 134.0, CH 7.63 (t, 7.6) 133.1, CH
8-OMe 3.29, s 51.6, CH3 3.12, s 51.4, CH3 8
11-OMe 3.25, s 56.7, CH3 3.15, s 55.7, CH3 11
9-OH 6.09 (d, 6.2)
10-OH 5.75 (d, 5.8)
NH-7 7.40, br s 9.89, s 5
a In CDCl3.
b In DMSO-d6.
c From H to C.





















































































and its diastereomer pseurotin A2,
35 revealed that 10 pos-
sessed the same relative stereochemistry as pseurotin A2,
based on almost identical 13C chemical shift values (Table S1,
ESI3). Similar optical rotation values for 10 and pseurotin A2,
the absolute configuration of which was established on the
basis of X-ray crystallographic analysis and the use of circular
dichroism (CD) spectroscopy,35 indicated that both com-
pounds should also have the same absolute configuration.
Molecular mechanics simulations as well as a comparison
of their NOESY spectra were carried out for both 9 (featuring a
9a-OH) and 10 (displaying a 9b-OH, Fig. 2). The proximity
between H-9 and 8-OMe was confirmed by a strong NOE
correlation from H-9 to 8-OMe in 10, indicating that the 9-OH
was in the b-configuration in 10. This fact was also
corroborated by the absence of an NOE between H-9 and
8-OMe in 9 when 9-OH was in the a-configuration. On this
basis 10 was identified as the previously unreported 9-epimer
of 11-O-methylpseurotin A for which the name 11-
O-methylpseurotin A2 is suggested.
Since DKP production was induced through a microbial co-
culture, which can be considered as a simulated competitive
environment, antibacterial activity was expected for these
compounds. However, none of the isolated compounds
showed significant antibacterial activity when screened
against Staphylococcus aureus and Escherichia coli (data not
shown). This result does not exclude that these compounds
were produced by the fungus to combat the existing bacteria in
the culture environment, but could also be due to the
compounds acting as quorum sensing inhibitors which do
not inevitably kill or inhibit the growth of a microbial strain
but instead modulate its phenotype, for instance via virulence
attenuation.36,37 Meanwhile, assays for trypanocidal and
leishmanicidal activities were performed on the isolated
compounds (Table 2). All tested compounds proved active
against these two parasites except brevianamide F (2) and 11-
O-methylpseurotin A (9). Fumitremorgin B (7) and verruculo-
gen (8) were the most potent growth inhibitors on both
parasites exhibiting EC50 values of 0.2 mM on Trypanosoma
brucei brucei and 3–4 mM on Leishmania donovani, followed by
12,13-dihydroxyfumitremorgin C (6) which exhibited an EC50
value of 7.4 mM on Trypanosoma brucei brucei. Although these
compounds proved moderate to potent inhibitors of these
parasites, they were not selective and showed pronounced
toxicity on MRC5 cells (normal human lung fibroblasts) which
suppressed further investigation and precluded their value as
a lead scaffold. These results were in agreement with the
Fig. 2 Selected COSY ( ) and NOESY ( ) correlations of 10 (a). Molecular mechanics models of the 9a-OH (in 9, b) and 9b-OH (in 10, c) indicated that the
observed NOE of H-9 to 8-OMe was only consistent with the 9b-OH stereochemistry in 10.
Table 2 Antiprotozoal activity of metabolites isolated from Aspergillus fumigatus MBC-F1-10a
Compound Trypanocidal activity Leishmanicidal activity Effect on MRC5 cells
2 n.a.b n.a. 9.23
3 16.1 19.5 2.5
4 n.a. 24.7 57.3
5 31.9 44.6 6.6
6 7.4 49.1 0.6
7 0.2 3.1 0.3
8 0.2 3.9 0.6
9 n.a. n.a. 50.7
10 n.a. 18.4 4.3
a Average EC50 in mM.
b n.a., not active up to 50 mM.





















































































literature where the fused pentacyclic DKPs showed pro-
nounced trypanocidal activity when compared with other
DKPs with a different skeleton.18 It could be concluded that
the 12,13-diol moiety in DKP derivatives plays an important
role in potentiating the antiparasitic effect of the fused
pentacyclic DKPs. 6-methoxyspirostatin B (4) showed a
moderate leishmanicidal activity with an EC50 value of 24.7
mM, but displayed selectivity in not being toxic toward MRC5
cells.
Conclusions
In conclusion, microbial co-culture (also referred to as mixed
fermentation) proved to be an efficient technique for the
production of microbial secondary metabolites. Although in
the last few years, various and diverse interactions between
bacteria and fungi have been investigated, the current study
describes an extreme example of induction of otherwise cryptic
biogenetic pathways. Apart from the multitude of structurally
diverse metabolites induced in A. fumigatus MBC-F1-10 by co-
cultivation with S. bullii strain C2, it is remarkable that
simulating bacterial presence by addition of well-established
quorum sensing metabolite, N-butyryl-DL-homoserine lactone,
resulted in inducing the biosynthesis of yet another two
metabolites, and none of these compounds was detected when
the fungus was cultivated alone. Application of mixed
fermentation for the discovery of new microbial metabolites
is still in its infancy, probably due to the fear of lack of
reproducibility.5 Our current study demonstrates that this
approach is capable of delivering reproducible metabolite
patterns, provided relevant fermentation parameters are first
established and then carefully maintained.
Experimental
General experimental procedures
Optical rotations were recorded using a Perkin-Elmer 343
polarimeter. UV and IR spectra were measured on a Perkin-
Elmer Lambda 25 UV-vis spectrometer and a Thermo Nicolet
IR 100 FT-IR spectrometer, respectively. NMR data were
acquired on a Varian Unity INOVA 600 MHz spectrometer.
High resolution mass spectrometric data were obtained using
a Thermo Instruments MS system (LTQ XL/LTQ Orbitrap
Discovery) coupled to a Thermo Instruments HPLC system
(Accela PDA detector, Accela PDA autosampler, and Accela
pump). The following conditions were used: capillary voltage
45 V, capillary temperature 320 uC, auxiliary gas flow rate 10–
20 arbitrary units, sheath gas flow rate 40–50 arbitrary units,
spray voltage 4.5 kV, mass range 100–2000 amu (maximum
resolution 30,000). HPLC separations were carried out using a
Phenomenex reversed-phase (C18, 250 6 10 mm, L 6 i.d.)
column connected to an Agilent 1200 series binary pump and
monitored using an Agilent photodiode array detector.
Detection was carried out at 220, 254, 280, 350, and 400 nm.
N-butyryl-DL-homoserine lactone was obtained from Sigma-
Aldrich. Diaion HP-20 was obtained from Resindion S.R.L., a
subsidiary of Mitsubishi Chemical Co., Binasco, Italy.
Microorganisms and fermentation
The S. bullii strain was isolated from the soil taken from the
Laguna de Chaxa of the Salar de Atacama (in the northern part
of the Atacama Desert, Chile) as described previously. The
first-stage seed culture was prepared by inoculation of an agar
grown culture into 100 mL of ISP2 broth (4.0 g yeast extract,
10.0 g malt extract, 4.0 g glucose, distilled water 1000 mL
adjusted to pH 7.2) for 24 h.
Aspergillus fumigatus strain MBC-F1-10 was isolated from the
S. bullii culture, purified on malt extract agar (15.0 g malt
extract, 15.0 g agar, distilled water 1000 mL adjusted to pH 7.2)
and identified by sequence comparison of its amplified ITS
region (GenBank accession number JN153038) with published
sequences obtained from GenBank as described previously.38
The fungal strain was inoculated in 10 6 100 mL malt extract
broth (15.0 g malt extract, distilled water 1000 mL adjusted to
pH 7.2 in the presence of 50 g Diaion HP-20 resin) for 5 days in
a rotary incubator at 28 uC with shaking at 150 rpm.
A set of experiments (a–g) were performed on these 2
cultures, each experiment was performed in triplicate on small
scale cultures (1 L) and monitored by HPLC while experiments
c and g were repeated on a larger scale basis with 3 L ISP2
medium. The time frame for experiment (c) was established
during 11 independent experiments, in which the addition of
the bacterial to the fungal culture was changed by 12 h each,
ranging from 0 h to 144 h, and maximum induction of
metabolites was observed after 72 h (data not shown). (a)
Bacteria alone: 1 mL S. bullii culture was transferred
aseptically to 100 mL fresh ISP2 broth and re-incubated using
the same conditions for 5 days. (b) Fungus alone: 1 mL fungal
culture was transferred aseptically to 100 mL fresh malt extract
broth and re-incubated using the same conditions for 5 days.
(c) Bacterial fungal interaction: 1 mL S. bullii culture was
transferred aseptically to 100 mL three day-established fungal





















































































culture in ISP2 broth and re-incubated using the same
conditions for 5 days. (d) Fungus with bacteria-free ISP2
broth: 1 mL fresh ISP2 broth was transferred aseptically to 100
mL fungal culture in malt extract broth and re-incubated using
the same conditions for 5 days. (e) Fungus with bacterial
extract: 0.5 mL biomass extract [(bacterial biomass obtained
from 100 mL bacterial culture for 3 days was extracted with
MeOH; the resulting extract was concentrated and the residue
dissolved in 1 mL MeOH:H2O (1 : 1)] was transferred
aseptically to 100 mL fungal culture in ISP2 broth and re-
incubated using the same conditions for 5 days. (f) Fungus
with dead bacterial cells: 1 mL autoclaved bacterial broth was
transferred aseptically to 100 mL fungal culture in ISP2 broth
and re-incubated using the same conditions for 5 days. (g)
Fungus with HSL: 1 mg L21 N-butyryl-DL-homoserine lactone
was added aseptically to the fresh fungal culture in ISP2 broth
and incubated using the same conditions for 7 days.
Extraction and isolation
The same procedure was performed for small and large scale
screening experiments. The harvested fermentation broth
from the fungal strain (ISP2, 3 L) was centrifuged at 3000
rpm for 20 min, and the HP20 resin together with the biomass
was washed with distilled water and then extracted with
methanol (5 6 200 mL). The successive MeOH extracts were
combined and concentrated in vacuo yielding 250 mL of
materials that were fractionated with n-hexane (3 6 200 mL),
CH2Cl2 (4 6 200 mL) and EtOAc (3 6 200 mL). The CH2Cl2
fraction was loaded on a Sephadex LH-20 column equilibrated
with MeOH-CH2Cl2 (1 : 1) and two fractions were collected.
The second fraction was purified by RP-HPLC using a gradient
of MeOH in H2O as eluent (50–100% over 70 min, 100% for 20
min) at a flow rate of 1.25 mL min21. HPLC of the large scale
of experiments (c and g) afforded the pure compounds 2 (14
mg), 3 (5 mg), 4 (6 mg), 5 (23 mg), 6 (6 mg), 7 (3 mg), 8 (2 mg), 9
(10 mg), 10 (7 mg), 11 (13 mg), and 12 (1.5 mg). 11-
O-methylpseurotin A2 (10): colorless powder [a]20D 213.8 (c
0.1, CH3OH); UV (MeCN) lmax (log s) 202 (3.92), 251 (3.22),
281 (2.80) nm; IR (film) umax 3244, 1710, 1680, 1605, 1122
cm21; 1H and 13C NMR, see Table 1; HRESIMS m/z 446.1809
[M+H]+ (calcd for C23H27NO8, 446.1809).
Antibacterial screening
The antibacterial activity of the isolated compounds was
evaluated against S. aureus ATCC25923 and E. coli ATCC25922
using the agar diffusion method.39
Antiprotozoal activity
Trypanosoma brucei brucei (bloodstream form 427, VSG 221)
and Leishmania donovani axenic amastigotes, (WHO design,
MHOM/SD/62/1S-CL2D) were used for this assay. Normal
human MRC5 cells (diploid foetal lung fibroblasts) were used
as a counter-screen for toxicity and non-selective inhibitors.
The full method was performed using the 384 well plate
adaptation of an assay described in the literature.40 In brief,
bloodstream-form T. brucei brucei cells were grown at 37 uC
and 5% CO2 in a modified HMI9 medium, L. donovani
amastigotes were grown axenically at 37 uC and 5% CO2 in
medium-199, while MRC5 cells were grown at 37 uC and 5%
CO2 in a humidified incubator in Eagle’s Minimal Essential
Medium.3 Different concentrations of the tested compounds
were examined in duplicate. Tested compounds were solubi-
lised to 10 mM in DMSO. 10-point, 1 in 3 dilution curves were
made from the compounds, and then 250 nL of each
compound was stamped into 384-well assay plate so that the
top concentration for the test compounds was 50 mM. 50 mL of
either T. brucei brucei or L. donovani culture was added to each
well at a density of 56 103 mL21. MRC5 cells were plated at 2
6 104 mL21 in 80 mL medium, allowed to adhere overnight,
before the compound, which had been pre-diluted in media,
was added to achieve a final top concentration of 50 mM. All
plates were incubated for 69 h at 37 uC in 5% CO2. Then,
resazurin (Sigma-Aldrich) dissolved in water was added to a
final concentration of 45.5 mM in each well and incubated for a
further 3–4 h. Plates were read for fluorescence on a Biotec
Instruments FLX 800 fluorescent plate reader at an excitation/
emission of 528/590 nm, with a filter cutoff at 550 nm. EC50
values were analysed using IDBS activity base XLFit 4.2 Model
205.
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